Drugs / Liberase Enzyme (Roche)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT04326036 Background | Mar 2020 → Aug 2023 | COVID-19, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, pulmonary alveolar proteinosis +1 | Black Tie Medical, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Liberase Enzyme (Roche) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04326036 ↗ |
| Modality | Protein / enzyme biologic | “Sterile Collagenase Blend to separate cSVF from the AD-SVF” NCT04326036 ↗ |